Does starting cannabis young raise the risk of opioid addiction later?
Early cannabis use and later opioid use disorder - the role of adverse childhood experiences, genetic liability and comorbid stimulant use
Researchers will look at existing health and genetic data to see if people who began using cannabis in their teens are more likely to develop opioid addiction, and how childhood trauma, genes, and stimulant use change that risk.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11124913 on NIH RePORTER |
What this research studies
This project analyzes large human datasets, including twin samples, to trace links between early cannabis use and later opioid use disorder. It combines genetic risk scores, reports of adverse childhood experiences, and measures of stimulant use to untangle which factors drive the association. The team will apply statistical models to existing human data rather than enroll new patients, and will consider animal study findings to help interpret biological mechanisms. Results are intended to clarify who is most at risk and why, to inform prevention efforts.
Who could benefit from this research
Good fit: Findings will be most relevant to people who began using cannabis during adolescence, especially those with childhood trauma, stimulant use, or a family history of substance problems.
Not a fit: People without any history of cannabis or opioid exposure, or whose experiences are not represented in the analyzed datasets, are unlikely to receive direct benefit.
Why it matters
Potential benefit: If successful, the work could help identify people at higher risk and guide prevention or early intervention efforts to reduce opioid addiction.
How similar studies have performed: Prior population and twin studies suggest links between early cannabis use and later opioid or stimulant problems and animal work shows possible biological effects, but combined large-scale genetic and trauma analyses are limited.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Agrawal, Arpana — Washington University
- Study coordinator: Agrawal, Arpana
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.